Overview

Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in NSCLC With Expansion Cohorts in NSCLC, Melanoma, and Colorectal Cancer

Status:
Unknown status

Trial end date:
2019-08-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine the safety and tolerability of entinostat used in combination with pembrolizumab in patients with Non-small Cell Lung Cancer. Additionally the purpose of the study is to assess how effective entinostat and pembrolizumab are in combination in patients with Non-small Cell Lung Cancer, Melanoma, and Mismatch-Repair Proficient Colorectal Cancer

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Syndax Pharmaceuticals

Collaborator:

Merck Sharp & Dohme Corp.

Treatments:

Antibodies
Entinostat
Pembrolizumab